License effective through December 2036
 |
| (Source: https://samsungbiologics.com/media/pr-materials) |
By PatenTrip
Samsung Electronics has secured a non-exclusive license to use a Korean patent held by KAIST for cell culture technology. The licensed patent, titled "Platform for preparing surface stimuli-responsive 3D multicellular spheroids and Use Thereof" (Registration No. KR1969115), covers a culture vessel with a hydrophobic polymer film—deposited with a water contact angle between 70° and 100°—and a method for manufacturing three-dimensional cell spheroids using the vessel.
Samsung Electronics registered the non-exclusive license in November 2024, and the license term extends from April 2019 until December 2036.
Under a non-exclusive license, the patent owner permits multiple parties to use the same patented technology, and retains the right to use the invention as well. In contrast, an exclusive license grants usage rights solely to a designated party, restricting both the patent owner and third parties from using the technology.
The cell culture patent summary explains that the invention involves inducing cell responses via the deposited polymer to form 3D cell spheroids. The process utilizes chemical vapor deposition techniques, including an initiator-assisted iCVD method, to modify the surface of the culture vessel.
KAIST notes that the technology enables a uniform and stable polymer coating, facilitating a relatively simple and rapid production of cell spheroids with enhanced cellular function. The platform is touted for its broad applicability—from basic cell research and disease studies to the development of implantable cell therapies.
This development follows a similar move in which Samsung previously secured a non-exclusive license for the Korean patent "Apparatus for automatic cardiopulmonary resuscitation and controlling method thereof" (Registration No. KR1956776), originally held by Seoul National University's Industry-Academic Cooperation Foundation.
Samsung registered that license in December 2022, with its effective term running from December 2022 to December 2036, and the patent's ownership was transferred to Blue Robin in 2023.
As of late September 2024, Samsung Electronics holds a 31.22% stake in its affiliate Samsung Biologics as the second-largest shareholder, while Samsung C&T tops the ownership structure with a 43.06% share.
 |
| A figure from the patent titled "Platform for preparing surface stimuli-responsive 3D multicellular spheroids and Use Thereof" (Registration No. KR1969115) owned by KAIST (Source: KIPRIS) |
By PatenTrip
Comments
Post a Comment